APE1.F Addex Therapeutics Ltd

Healthcare Biotechnology Frankfurt Exchange
2.52 EUR
Close of Nov 12, 2026
2.28 7.50
Market cap
EUR 4.42M
P/E
-
P/B
2.11x
ROE
-362.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is APE1.F undervalued?

Graham number

The Graham number of Addex Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Addex Therapeutics Ltd fundamental analysis

No fundamental analysis for Addex Therapeutics Ltd yet.

Addex Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for un…

Full company profile